糖尿病神经病变过程中非编码 RNA 的作用及机制.

BACKGROUND: Persistent hyperglycemia has been identified as promoting neurovascular dysfunction, leading to irreversible endothelial dysfunction, increased neuronal apoptosis, oxidative stress and inflammation. These changes in combination or alone lead to microvascular and macrovascular lesions as well as progressive neuropathy. Noncoding RNAs may provide a new strategy for understanding the etiology, pathogenesis and treatment of the disease. OBJECTIVE: To review the role and mechanism of noncoding RNAs in the occurrence and development of diabetic peripheral neuropathy by reviewing relevant literature at home and abroad, in order to provide new ideas and approaches for noncoding RNAs in the prevention, diagnosis and treatment of diabetes neuropathy. METHODS: CNKI and PubMed were retrieved for relevant literature published from database inception to 2022. The key words were “noncoding RNA; lncRNA; miRNA; diabetes peripheral neuropathy; expression profile” in Chinese and English, respectively. The retrieved documents were summarized and analyzed, and 61 articles were finally selected for further review. RESULTS AND CONCLUSION: (1) Noncoding RNA plays a key role in the pathophysiological process of diabetic peripheral neuropathy. Among the most widely studied regulatory noncoding RNA species, there are long noncoding RNAs, circular RNAs and microRNAs. (2) Through the regulation of noncoding RNAs, the activation or inhibition of related cell pathways, inflammatory genes and downstream-related cytokines will inhibit cell apoptosis, improve inflammation, and thus change the expression of target genes to participate in the process of diabetic neuralgia. (3) Although many microRNAs and long noncoding RNAs have been found to participate in diabetic peripheral neuropathy, the mechanisms of many noncoding RNAs are unclear, and the same noncoding RNAs may play different roles in different modes. Therefore, it is necessary to further study their action modes in disease etiology and pathology, thereby clarifying their role in the pathogenesis of diabetic peripheral neuropathy. However, the criteria for evaluating noncoding RNA activity have not yet been established, and further research is needed on which specific noncoding RNAs play a dominant regulatory role. (4) MicroRNAs, long noncoding RNAs and their target genes can regulate progressive neuropathy, which are expected to become new targets for the clinical prevention and treatment of diabetic peripheral neuropathy and new biomarkers for the development and prognosis of diabetic peripheral neuropathy. [ABSTRACT FROM AUTHOR]